Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Abstract

Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.

Joel Kremer, Mark Genovese, Grant W Cannon, Jacques Caldwell, John Cush, Daniel E Furst, Michael Luggen, Ed Keystone, Joan Bathon, Arthur Kavanaugh, Eric Ruderman, Patricia Coleman, David Curtis, Elliott Kopp, Seth Kantor, Michael Weisman, Jonathan Waltuck, Herbert B Lindsley, Joseph Markenson, Bruce Crawford, Indra Fernando, Karen Simpson and Vibeke Strand
The Journal of Rheumatology August 2004, 31 (8) 1521-1531;
Joel Kremer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Genovese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grant W Cannon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques Caldwell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Cush
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel E Furst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Luggen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ed Keystone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joan Bathon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur Kavanaugh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Ruderman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Coleman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Curtis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elliott Kopp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seth Kantor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Weisman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Waltuck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Herbert B Lindsley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Markenson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Crawford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Indra Fernando
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Simpson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vibeke Strand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

OBJECTIVE: To obtain additional safety and efficacy data on leflunomide (LEF) treatment in combination with methotrexate (MTX) therapy in an open-label extension study in patients with rheumatoid arthritis (RA). METHODS: Following a 24 week, randomized, double-blind trial of adding placebo (PLA) or LEF to stable MTX therapy, patients could enter a 24 week extension. Subjects randomized to LEF and MTX continued treatment [(LEF/LEF) + MTX]. Subjects randomized to PLA and MTX switched to LEF (10 mg/day, no loading dose) and MTX [(PLA/LEF) + MTX]. The double-blind regarding initial randomization was maintained. RESULTS: For subjects in the extension phase, American College of Rheumatology 20% (ACR20) responder rates for the (LEF/LEF) + MTX group were maintained from Week 24 (57/96, 59.4%) to Week 48 (53/96, 55.2%). ACR20 responder rates improved in patients switched to LEF from PLA at Week 24 [(PLA/LEF) + MTX] from 25.0% (24/96) at Week 24 to 57.3% (55/96) at Week 48. Patients in the extension who switched from PLA to LEF without a loading dose exhibited a lower incidence of elevated transaminases compared to patients initially randomized to LEF. Diarrhea and nausea were less frequent during the open-label extension in patients who did not receive a LEF loading dose. CONCLUSION: Response to therapy was maintained to 48 weeks of treatment in patients who continued to receive LEF and MTX during the extension. Importantly, ACR20 response rates after 24 weeks of LEF therapy were similar between patients switched from PLA to LEF without loading dose, and those who received a loading does of LEF (100 mg/day x 2 days) at randomization. Fewer adverse events were reported in patients switched to LEF without a loading dose.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 31, Issue 8
1 Aug 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
Joel Kremer, Mark Genovese, Grant W Cannon, Jacques Caldwell, John Cush, Daniel E Furst, Michael Luggen, Ed Keystone, Joan Bathon, Arthur Kavanaugh, Eric Ruderman, Patricia Coleman, David Curtis, Elliott Kopp, Seth Kantor, Michael Weisman, Jonathan Waltuck, Herbert B Lindsley, Joseph Markenson, Bruce Crawford, Indra Fernando, Karen Simpson, Vibeke Strand
The Journal of Rheumatology Aug 2004, 31 (8) 1521-1531;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
Joel Kremer, Mark Genovese, Grant W Cannon, Jacques Caldwell, John Cush, Daniel E Furst, Michael Luggen, Ed Keystone, Joan Bathon, Arthur Kavanaugh, Eric Ruderman, Patricia Coleman, David Curtis, Elliott Kopp, Seth Kantor, Michael Weisman, Jonathan Waltuck, Herbert B Lindsley, Joseph Markenson, Bruce Crawford, Indra Fernando, Karen Simpson, Vibeke Strand
The Journal of Rheumatology Aug 2004, 31 (8) 1521-1531;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire